NovoCure Ltd. (NVCR)
12.08
-0.04
(-0.29%)
USD |
NASDAQ |
Dec 08, 16:00
12.08
0.00 (0.00%)
After-Hours: 16:53
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.352B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -54.47% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.079 |
| Price to Book Value | 3.962 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 2.338 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.17% |
Profile
| NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey. |
| URL | http://www.novocure.com |
| Investor Relations URL | https://www.novocure.com/investor-relations/investor-relations/home |
| HQ State/Province | Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey. |
| URL | http://www.novocure.com |
| Investor Relations URL | https://www.novocure.com/investor-relations/investor-relations/home |
| HQ State/Province | Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |